Total number of patients, n | 114 |
Age, years, Median (Range) | 70 (40-96) |
Gender, male/female | 95/19 |
Recurrence within 24 months, n (%) | 38 (33.0) |
pT Stage of first recurrence within 24 months | |
pTa | 25 (65.8) |
pT1 | 5 (13.1) |
≥ pT2 | 3 (7.9) |
Cis | 11 (28.9) |
G1 | 15 (39.5) |
G2 | 9 (23.6) |
G3 | 9 (23.6) |
Interval between last bladder cancer episode and urine marker sampling, months, Median (Range) | 6 (3-84) |
pT/Grade last bladder cancer episode before urine marker sampling, n (%) | |
pTa | 74 (64.9) |
pT1 | 28 (24.5) |
Cis (pure) | 12 (10.5) |
Cis (concomitant) | 11 (9.6) |
G1 | 51 (44.7) |
G2 | 35 (30.1) |
G3 | 16 (14.0) |
Highest pT/Grade in patient’s history before urine marker sampling, n (%) | |
pTa | 71 (62.3) |
pT1 | 32 (27.3) |
Cis (pure) | 11 (9.6) |
Cis (concomitant) | 16 (14.0) |
G1 | 47 (41.2) |
G2 | 39 (34.2) |
G3 | 17 (14.9) |
Time to recurrence, months, Median (Range) | 12.5 (3-24) |
Patients developing progression, n (%) | 13 (11.4) |
Time to progression, months, Median (Range) | 11 (3-24) |